| EPF038 | The Gender Equality Forum and the 40 billion dollar question: where is HIV? | E-poster | Sexual- and/or gender-based inequalities, inequities and violence |
| EPD397 | The force of HIV stigma: loops of negative feedback of social inequalities for women's access to HIV care in Chiapas, Mexico | E-poster | Societal stigma towards people living with HIV and key populations |
| PESUB26 | The first-in-human clinical trial of STP0404, a novel potent HIV-1 allosteric integrase inhibitor | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| EPC289 | The first study of psychoactive substance use and drug checking practices among participants of electronic dance music Events in Ukraine | E-poster | Access to harm reduction interventions |
| EPE365 | The first multi-sectoral, user-driven data pipeline to adaptively manage HIV prevention programs in Malawi | E-poster | Approaches to using data to improve programming |
| EPE275 | The final stages of an epidemic? Learning from London's community-led HIV response | E-poster | Community participation in systems for health, including community-led and key population-led health systems |
| PESAE02 | The fidelity of a pharmacy-based PrEP delivery model in Kenya: an unannounced standardized patient actor assessment | Poster exhibition | Implementation science of scaling up prevention (including PrEP) |
| EPC394 | The feasibility and acceptability of prison-based voluntary assisted partner notification among incarcerated men with HIV and their community partners | E-poster | HIV testing to support identification of new cases of people living with HIV |
| EPD259 | The feasibility and acceptability of engaging the brothers and sisters of Latinx gay men (LGM) to promote PrEP use | E-poster | Couples- or family-centred approaches |
| OAB0202 | The fast and the continuous: dolutegravir-based antiretroviral therapy achieves impressive viral load suppression in CALHIV in the short- and long-term | Oral abstract session with live Q&A | ARV management strategies in paediatric and adolescent populations |